secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-08-06T20:17:59+00:00
Accession:  0001437749-26-026280
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart reports Q2 2026 net loss $13.5M; Phase 2b sentinel safety data positive
------------------------------------------------------------------------------

- Net loss $13.5M ($0.06 per share) vs $15.0M loss in Q2 2025; revenue $27.2M (down from $39.7M).
- Cash $64.0M; runway into Q2 2027; BARDA contract total authorized funding $344.8M.
- Phase 2b sentinel cohort (400 participants) showed no vaccine-related SAEs; most common AEs: fatigue, headache.
- Topline efficacy data from full ~5,000-participant study expected H1 2027.
- R&D expenses $33.7M (down 32% YoY); G&A $6.6M (up 43% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/0001437749-26-026280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/vxrt20260806_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer